The year in cardiology arrhythmias and pacing

█ Current opinion

Authors:
A. John Camm¹, Gregory Y.H. Lip^2,3, Richard Schilling⁴, Hugh Calkins⁵, and Jan Steffel^6
1St. George’s University of London, Cardiology Clinical Academic Group, Molecular & Clinical Sciences Institute, Cranmer Terrace, London, SW19 0RE, London, UK;
²Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital, Liverpool, UK;
³Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark;
⁴Barts Heart Centre, London, UK;
⁵Johns Hopkins Medical Institutions, Baltimore, MD, USA; and
⁶Department of Cardiology, Division of Electrophysiology, University Hospital Zurich, Switzerland

Preamble

During this last year, there has been much progress with regard to anticoagulant and ablation therapy for atrial fibrillation (AF). Apart from recently issued European Society of Cardiology Guidelines for the mana­gement of patients with supraventricular arrhythmias, there has been little progress in research in this field. Ventricular arrhythmias and device therapy have seen modest progress.

ISSUE: CARDIOLOGIA HUNGARICA | 2020 | VOLUME 50, ISSUE 3 

click here to read the full article

click here to read the pdf